ClinicalTrials.gg
CompletedNCT04688320Updated Apr 2, 2025Results posted

Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE

A Phase 3 interventional study of Recombinant nonimmunogenic staphylokinase and Alteplase in Massive Pulmonary Embolism, sponsored by Supergene, LLC. Completed at 23 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Supergene, LLC · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing Tissue Plasminogen Activator in Pulmonary Embolism — 1 open to participants now, 4 under way, 2 of them phase 3. Tissue Plasminogen Activator · Pulmonary Embolism.

Enrollment
4th of 15
310 · median 118
Started
2020
with 2 others
Phase 3
7 of 15
none open now
Registered
14th of 15
by date
Lead sponsor
1 of 15
Supergene, LLC

Among the 15 studies testing Tissue Plasminogen Activator in Pulmonary Embolism, this one is the 4th largest by enrollment, is one of 3 that started in 2020, is one of 7 in phase 3, and was the 14th registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

1 of the 15 studies testing Tissue Plasminogen Activator in Pulmonary Embolism is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Tissue Plasminogen Activator

Tissue Plasminogen Activator: first FDA approval 1987 (ACTIVASE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing Tissue Plasminogen Activator in Pulmonary Embolism, or all of them as a file.
02

Study summary

Objective: to evaluate the efficacy and safety of the Recombinant Non-immunogenic Staphylokinase with its single bolus administration in comparison with the bolus-infusion administration of the Alteplase in patients with massive pulmonary embolism

Read the detailed description

The main goal of treating massive PE is to save the lives of patients by restoring pulmonary perfusion, preventing the development of chronic postembolic pulmonary hypertension and recurrent PE. According to data of clinical trials, with timely initiation of therapy for massive pulmonary embolism, mortality can be significantly reduced.

Recombinant protein which contains aminoacid sequence of staphylokinase - Fortelizin® (the active substance is Forteplase). It is single chain molecula, consists of 138 aminoacids, weight 15.5 kDa. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. This complex activates plasminogen trapped in the thrombus. The plasmin-staphylokinase complex and plasmin bound to fibrin are protected from inhibition by alpha2-antiplasmin. Once liberated from the clot (or generated in plasma), however, they are rapidly inhibited by alpha2-antiplasmin. This selectivity of action confines the process of plasminogen activation to the thrombus, preventing excessive plasmin generation, alpha2-antiplasmin depletion, and fibrinogen degradation in plasma. In rabbits anti forteplase antibodies are not produced. It was achieved by replacement of amino acids in immunogenic epitop of molecule staphylokinase. Blood fibrinogen decrease after i.v. injection of Fortelyzin less 10% within first 24 hours. Angiographic data suggests that restoration of coronary blood flow appears in up to 80% of patients with STEMI after i.v. injection of Fortelyzin.

The main objectives of the study: to assess the efficacy, safety and possible adverse events of the drug Recombinant Non-immunogenic Staphylokinase with its single bolus administration in comparison with the bolus-infusion administration of the drug Alteplase® in patients with massive pulmonary embolism.

Study Design. Multicenter, open-label, randomized, comparative clinical study of non-inferiority study of efficacy and safety in parallel groups. At clinical centers, patients will be equally randomly distributed by the "envelope" method into two groups of 155 patients each (310 people in total, including 10% of those who may have dropped out)to receive Recombinant Non-immunogenic Staphylokinase or Alteplase®.

The drugs will be administered after the signed informed consent. Recombinant Non-immunogenic Staphylokinase will be administered intravenously at a dose of 15 mg as a single bolus for 10-15 seconds. Alteplase® will be administered in accordance with the instructions for use.

Patients will be monitored for 30 days from the moment of randomization: in the intensive care unit up to 7 days, after it in the hospital until discharge - an average of 14 days and an outpatient visits on the 30th day. The recruitment of patients for the study will be competitive.

03

Conditions studied

  • Massive Pulmonary Embolism

Browse trials for

Keywords

  • Massive pulmonary embolism
  • Fibrinolysis
  • Recombinant Non-immunogenic Staphylokinase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 and over
  • Verified diagnosis of massive PE (using MSCT with PA contrast)
  • Signs of overload / dysfunction of the right ventricle (at least one) in combination with persistent arterial hypotension or shock
  • Patient consent to use reliable methods throughout the study and for 3 weeks after:

    • women who have a negative pregnancy test and use the following contraceptives: intrauterine devices, oral contraceptives, contraceptive patch, prolonged injectable contraceptives, double barrier method of contraception. Women who are not fertile can also take part in the study (documented conditions: hysterectomy, tubal ligation, infertility, menopause for more than 1 year);
    • men using barrier contraception. The study may also involve men who are not fertile (documented conditions: vasectomy, infertility)
  • Availability of signed and dated of the patient to participate in the study.

Exclusion criteria

Exclusion Criteria:

    • Increased risk of bleeding:

      • Extensive bleeding at present or within the previous 6 months, hemorrhagic diathesis;
      • Intracranial (including subarachnoid) hemorrhage at present or in history, suspected hemorrhagic stroke;
      • A history of hemorrhagic stroke or stroke of unknown etiology;
      • Ischemic stroke or within the last 6 months, except for the current acute ischemic stroke within 4.5 hours;
      • A history of diseases of the central nervous system (including neoplasms, aneurysms, surgery on the brain or spinal cord);
      • Major surgery or major trauma within the previous 3 months, recent traumatic brain injury;
      • Long-term or traumatic cardiopulmonary resuscitation (> 2 min), delivery within the previous 10 days, recent puncture of an uncompressible blood vessel (eg, subclavian or jugular vein);
      • Severe liver disease, including liver failure, cirrhosis, portal hypertension (including esophageal varices) and active hepatitis;
      • Confirmed gastric or duodenal ulcer within the last three months;
      • Neoplasm with an increased risk of bleeding;
      • Concurrent administration of oral anticoagulants, for example, warfarin with an > 1.3;
      • Arterial aneurysms, developmental defects of arteries / veins;
      • Severe uncontrolled arterial hypertension;
      • Acute pancreatitis;
      • Bacterial endocarditis, pericarditis;
      • suspicion of aortic dissecting aneurysm;
      • any other conditions, in the opinion of the doctor, associated with a high risk of bleeding.
  • Lactation, pregnancy
  • Known to Alteplase, Fortelizin.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    Recombinant nonimmunogenic staphylokinase

    lyophilisate for preparation of a solution for intravenous administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, intravenously as a quick single bolus injection for 10-15 seconds, regardless of body weight.

    Drug: Recombinant nonimmunogenic staphylokinase

  • Experimental
    Alteplase

    Alteplase® is administered in accordance with the instructions for use for pulmonary embolism( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.

    Drug: Alteplase

Interventions

06

What researchers measure

Primary outcomes

  1. Death From All Causes

    The efficacy is evaluated in terms of the number of deaths from all causes

    Time frame: within 7 days

Secondary outcomes

  1. Systolic Pulmonary Artery Pressure Measures (V1, V2, V4, V5)

    The efficacy is evaluated in terms of systolic pulmonary artery pressure values

    Time frame: baseline and day 1, 7, 14 after randomisation

  2. Haemodynamic Collapse

    The efficacy is evaluated in terms of the number of haemodynamic collapse

    Time frame: within 7 days

  3. Recurrent Pulmonary Embolism (PE)

    The efficacy is evaluated in terms of the number of recurrent PE

    Time frame: within 7 days

  4. Death From PE

    The efficacy is evaluated in terms of the number of deaths from PE

    Time frame: within 30 days

  5. Death From All Causes

    The efficacy is evaluated in terms of the number of deaths from all causes

    Time frame: within 30 days

  6. Haemodynamic Collapse Within 7 Days + Recurrent PE Within 7 Days + Death From All Causes Within 30 Days

    The efficacy is evaluated in terms of the number of haemodynamic collapse + recurrent PE + deaths from all causes

    Time frame: within 30 days

  7. Safety Endpoint - Haemorrhagic Stroke

    The safety is evaluated in terms of the number of haemorrhagic stroke within 7 days of randomisation

    Time frame: within 7 days

  8. Safety Endpoint - BARC Type 3+5 Bleeding

    The safety is evaluated in terms of the number of BARC type 3+5 bleeding. Type 3a: overt bleeding plus a hemoglobin drop of 3 to 5 g/dL; any transfusion with overt bleeding. Type 3b: overt bleeding plus a hemoglobin drop of 5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring intravenous vasoactive agents. Type 3c: intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal); subcategories confirmed by autopsy or imaging, or lumbar puncture; intraocular bleed compromising vision. Type 5a: probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious. Type 5b: definite fatal bleeding; overt bleeding or autopsy, or imaging confirmation.

    Time frame: within 30 days

  9. Safety Endpoint - Number and Severity of Serious Adverse Events (SAEs)

    The safety is evaluated in terms of the number and severity of serious adverse events (SAEs)

    Time frame: within 30 days

07

Results

Posted Apr 2, 2025

Participant flow

Participant flow — Overall Study
MilestoneRecombinant Nonimmunogenic StaphylokinaseAlteplase
Started155155
Completed145146
Not completed109

Outcome measures

PrimaryDeath From All Causes

The efficacy is evaluated in terms of the number of deaths from all causes

Time frame:
within 7 days
Reported as:
Count of participants · Participants
Death From All Causes
ParticipantsRecombinant Nonimmunogenic StaphylokinaseAlteplase
Death From All Causes34
Statistical analysis
  • Recombinant Nonimmunogenic Staphylokinase vs Alteplase · Welch's t-test · p = <0.05 · Odds ratio (or): 0.75 · 95% CI 0.11 to 4.52
SecondarySystolic Pulmonary Artery Pressure Measures (V1, V2, V4, V5)

The efficacy is evaluated in terms of systolic pulmonary artery pressure values

Time frame:
baseline and day 1, 7, 14 after randomisation
Reported as:
Median · mm Hg
Systolic Pulmonary Artery Pressure Measures (V1, V2, V4, V5)
mm HgRecombinant Nonimmunogenic StaphylokinaseAlteplase
PASP on baseline59 (50 to 69)58 (51 to 69)
PASP on day 144 (36 to 52)42 (36 to 50)
PASP on day 736 (31 to 44)35 (29 to 41)
PASP on day 1435 (30 to 41)35 (28 to 41)
SecondaryHaemodynamic Collapse

The efficacy is evaluated in terms of the number of haemodynamic collapse

Time frame:
within 7 days
Reported as:
Number · events
Haemodynamic Collapse
eventsRecombinant Nonimmunogenic StaphylokinaseAlteplase
Haemodynamic Collapse13
SecondaryRecurrent Pulmonary Embolism (PE)

The efficacy is evaluated in terms of the number of recurrent PE

Time frame:
within 7 days
Reported as:
Number · events
Recurrent Pulmonary Embolism (PE)
eventsRecombinant Nonimmunogenic StaphylokinaseAlteplase
Recurrent Pulmonary Embolism (PE)12
SecondaryDeath From PE

The efficacy is evaluated in terms of the number of deaths from PE

Time frame:
within 30 days
Reported as:
Count of participants · Participants
Death From PE
ParticipantsRecombinant Nonimmunogenic StaphylokinaseAlteplase
Death From PE42
SecondaryDeath From All Causes

The efficacy is evaluated in terms of the number of deaths from all causes

Time frame:
within 30 days
Reported as:
Count of participants · Participants
Death From All Causes
ParticipantsRecombinant Nonimmunogenic StaphylokinaseAlteplase
Death From All Causes64
SecondaryHaemodynamic Collapse Within 7 Days + Recurrent PE Within 7 Days + Death From All Causes Within 30 Days

The efficacy is evaluated in terms of the number of haemodynamic collapse + recurrent PE + deaths from all causes

Time frame:
within 30 days
Reported as:
Number · events
Haemodynamic Collapse Within 7 Days + Recurrent PE Within 7 Days + Death From All Causes Within 30 Days
eventsRecombinant Nonimmunogenic StaphylokinaseAlteplase
Haemodynamic Collapse Within 7 Days + Recurrent PE Within 7 Days + Death From All Causes Within 30 Days89
SecondarySafety Endpoint - Haemorrhagic Stroke

The safety is evaluated in terms of the number of haemorrhagic stroke within 7 days of randomisation

Time frame:
within 7 days
Reported as:
Number · events
Safety Endpoint - Haemorrhagic Stroke
eventsRecombinant Nonimmunogenic StaphylokinaseAlteplase
Safety Endpoint - Haemorrhagic Stroke03
SecondarySafety Endpoint - BARC Type 3+5 Bleeding

The safety is evaluated in terms of the number of BARC type 3+5 bleeding. Type 3a: overt bleeding plus a hemoglobin drop of 3 to 5 g/dL; any transfusion with overt bleeding. Type 3b: overt bleeding plus a hemoglobin drop of 5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring intravenous vasoactive agents. Type 3c: intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal); subcategories confirmed by autopsy or imaging, or lumbar puncture; intraocular bleed compromising vision. Type 5a: probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious. Type 5b: definite fatal bleeding; overt bleeding or autopsy, or imaging confirmation.

Time frame:
within 30 days
Reported as:
Number · events
Safety Endpoint - BARC Type 3+5 Bleeding
eventsRecombinant Nonimmunogenic StaphylokinaseAlteplase
Safety Endpoint - BARC Type 3+5 Bleeding05
SecondarySafety Endpoint - Number and Severity of Serious Adverse Events (SAEs)

The safety is evaluated in terms of the number and severity of serious adverse events (SAEs)

Time frame:
within 30 days
Reported as:
Number · events
Safety Endpoint - Number and Severity of Serious Adverse Events (SAEs)
eventsRecombinant Nonimmunogenic StaphylokinaseAlteplase
Safety Endpoint - Number and Severity of Serious Adverse Events (SAEs)917

Adverse events

Collected over 30 days.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Recombinant Nonimmunogenic Staphylokinase6/145 (4.1%)9/145 (6.2%)72/155 (46.5%)
Alteplase4/146 (2.7%)17/146 (11.6%)86/155 (55.5%)
Most frequent serious events
Most frequent serious events
EventRecombinant Nonimmunogenic StaphylokinaseAlteplase
Death from all causesCardiac disorders6/1454/146
Haemodynamic collapseCardiac disorders1/1453/146
Haemorrhagic strokeNervous system disorders0/1453/146
Recurrent PECardiac disorders1/1452/146
Cerebral oedemaNervous system disorders0/1452/146
Ischaemic strokeNervous system disorders1/1450/146
Brainstem damageNervous system disorders0/1451/146
Haematoma of the thighCardiac disorders0/1451/146
Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders0/1451/146
Most frequent other events
Most frequent other events
EventRecombinant Nonimmunogenic StaphylokinaseAlteplase
HematuriaBlood and lymphatic system disorders72/15586/155

Baseline characteristics

310 patients were randomly assigned to receive either non-immunogenic staphylokinase (n=155) or alteplase (n=155)

Age, Categorical
Age, Categorical(Participants)Recombinant Nonimmunogenic StaphylokinaseAlteplaseTotal
<=18 years000
Between 18 and 65 years7594169
>=65 years8061141
Age, Continuous
Age, Continuous(years)Recombinant Nonimmunogenic StaphylokinaseAlteplaseTotal
Mean64 ± 1362 ± 1363 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)Recombinant Nonimmunogenic StaphylokinaseAlteplaseTotal
Female8474158
Male7181152
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Recombinant Nonimmunogenic StaphylokinaseAlteplaseTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White155155310
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Recombinant Nonimmunogenic StaphylokinaseAlteplaseTotal
Russia155155310
Body mass index, kg/m^2
Body mass index, kg/m^2(kg/m^2)Recombinant Nonimmunogenic StaphylokinaseAlteplaseTotal
Mean32 ± 631 ± 632 ± 6
Pulmonary Embolism Severity Index (PESI) score
Pulmonary Embolism Severity Index (PESI) score(score)Recombinant Nonimmunogenic StaphylokinaseAlteplaseTotal
Median135 (116 to 150)128 (113 to 145)132 (115 to 147)
PESI class V patients
PESI class V patients(Participants)Recombinant Nonimmunogenic StaphylokinaseAlteplaseTotal
Count of participants10382185

9 further baseline measures are reported on the registry.

08

Study locations

23 sites
  • V.F. Dolgopolov Vyselki Central District Hospital
    Vyselki, Krasnodar Region 353100, Russian Federation
  • Sergiyev Posad Regional Clinical Hospital
    Sergiyev Posad, Moscow Region 141301, Russian Federation
  • Belgorod Regional Clinical Hospital of St. Joseph
    Belgorod, 308007, Russian Federation
  • Kuzbass Cardiology center
    Kemerovo, 650002, Russian Federation
  • Krasnoyarsk Regional Clinical Hospital
    Krasnoyarsk, 660022, Russian Federation
  • Kursk Regional Clinical Hospital
    Kursk, 305007, Russian Federation
  • D.D. Pletnev City Clinical Hospital
    Moscow, 105077, Russian Federation
  • I.V. Davydovskii City Clinical Hospital
    Moscow, 109240, Russian Federation
  • S.S. Yudin City Clinical Hospital
    Moscow, 115446, Russian Federation
  • V.V. Vinogradov City Clinical Hospital
    Moscow, 117292, Russian Federation
  • V.V. Veresaev City Clinical Hospital
    Moscow, 127644, Russian Federation
  • N.V. Sklifosovsky Research Institute for Emergency Medicine
    Moscow, 129090, Russian Federation
  • S.P. Botkin City Clinical Hospital
    Moscow, Russian Federation
  • Murmansk Regional Clinical Hospital
    Murmansk, 183047, Russian Federation
  • N.N. Burdenko Penza Regional Clinical hospital
    Penza, 440026, Russian Federation
  • G.A. Zakharyin Clinical hospital №6
    Penza, 440071, Russian Federation
  • Saint Petersburg "Mariinskaya" City Hospital
    Saint Petersburg, 191014, Russian Federation
  • Holy Martyr Elizabeth Saint Petersburg City Hospital
    Saint Petersburg, 195257, Russian Federation
  • V.P. Polyakov Samara Regional Clinical Cardiology Dispensary
    Samara, 443070, Russian Federation
  • Saratov Regional Clinical Cardiology Dispensary
    Saratov, 410039, Russian Federation
  • Tver Regional Clinical Hospital
    Tver, 170036, Russian Federation
  • City Clinical hospital №4
    Vladimir, 600009, Russian Federation
  • City Clinical Hospital of Emergency №25
    Volgograd, 400138, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jul 2023, 31 months.

Results were first posted in Apr 2025, 1 year 8 months after primary completion.

Of 31 phase 3 interventional studies under Pulmonary Embolism, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2020
First posted
Dec 29, 2020
StartActual
Dec 15, 2020
Primary completionActual
Jul 27, 2023
CompletionActual
Jul 27, 2023
Results first posted
Apr 2, 2025
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04688320
Lead sponsor
Supergene, LLC
Responsible party
Sponsor
First posted
Dec 29, 2020
Start date
Dec 15, 2020
Primary completion
Jul 27, 2023
Completion
Jul 27, 2023
Results posted
Apr 2, 2025
Last update
Apr 2, 2025

Study contacts

Alexander I Kirienko, MD, PhD
principal investigator · Pirogov Russian National Research Medical University
Sergey S Markin, MD, PhD
study director · Supergene, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: auR protein, Staphylococcus aureus · Tissue Plasminogen Activator

Start the discussion